OWC Pharmaceutical Research Corp (OWCP)

[skitahoe]

People need to remember that the staff of the company are taking less pay than they would make working for others, but getting the remainder in stock. This by itself is dilutive by the way people are counting every share.

In a company in the developing stage that OWCP is, most companies would be diluting far more to afford what they need to do. The company has worked very conservatively to keep the costs of their efforts down. They run their trials in an Israeli hospital where they can do the work for less than if they opened the trial to multiple clinical sites. Eventually trials will get so large that they'll need to be run at multiple sites, probably in multiple countries, but for now they've done them inexpensively, but that might be contributing to the length of the trial.

I'm not saying they should do otherwise, but what would many of you be saying if they had issued 50 million more shares, but the safety trial was completed a couple months ago, and others started a month or two earlier than they're scheduled to.

I think the company is doing things well, I openly state things I'd like to see changed, but even if what I suggest did elevate the stock to a degree at this point, I recognize that long term it would make no difference. In just a few year if the company isn't acquired, I believe that you'll be able to purchase some products in drug stores, and many others in cannabis stores. The company will sell at a solid P/E ration of it's earnings. That will be totally independent of anything they reveal today about what they're doing, what's important is what they're doing, not what they're saying.

Gary